"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,DE,T2,DE 69129463 T2,162-677-497-429-231,1998-09-17,1998,DE 69129463 T,1991-09-13,EP 9101780 W;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,VERWENDUNG VON SUBSTANZEN IN PARTIKELFORM,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON,,https://lens.org/162-677-497-429-231,Granted Patent,no,0,0,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,0,0,,,,EXPIRED
2,DE,D1,DE 69129463 D1,148-740-939-410-303,1998-06-25,1998,DE 69129463 T,1991-09-13,EP 9101780 W;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,VERWENDUNG VON SUBSTANZEN IN PARTIKELFORM,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON,,https://lens.org/148-740-939-410-303,Granted Patent,no,0,0,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,0,0,,,,EXPIRED
3,WO,A1,WO 2002/074165 A1,066-845-071-559-928,2002-09-26,2002,US 0122914 W,2001-07-19,US 80938301 A,2001-03-15,JOINT IMAGING SYSTEM UTILIZING MAGNETIC RESONANCE IMAGING AND ASSOCIATED METHODS,"A magnetic resonance imaging system (10) and method for imaging joint regions are disclosed which utilize blood pool contrast agents and particular magnetic resonance imaging parameters, including fat-suppression, to obtain medically useful images of joints. In particular, the methods and apparatus provide medical personnel with accurate and detailed joint images, including joint spaces, which are useful for various therapeutic and diagnostic applications.",UNIV CALIFORNIA;;FILLER AARON G,FILLER AARON G,,https://lens.org/066-845-071-559-928,Patent Application,yes,1,0,2,2,0,A61B5/055;;A61B5/415;;A61B5/416;;A61B5/418;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/415;;A61B5/4504;;A61B5/416;;A61B5/055;;A61B5/418,A61B5/055,,0,0,,,,PENDING
4,AT,T1,AT E166233 T1,035-939-256-076-52X,1998-06-15,1998,AT 91916129 T,1991-09-13,GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,VERWENDUNG VON SUBSTANZEN IN PARTIKELFORM,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON GERSHON,,https://lens.org/035-939-256-076-52X,Granted Patent,no,0,0,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,0,0,,,,DISCONTINUED
5,EP,A4,EP 1675771 A4,156-955-600-562-541,2006-11-08,2006,EP 04800898 A,2004-11-04,US 2004/0037282 W;;US 54666404 P,2004-02-20,NEEDLE GUIDE,,POINT GUARD MEDICAL INC,FILLER AARON G,,https://lens.org/156-955-600-562-541,Search Report,no,10,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,B65B1/04;;A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14,,0,0,,,,DISCONTINUED
6,WO,A3,WO 2005/081708 A3,154-320-077-204-632,2005-12-22,2005,US 2004/0037282 W,2004-11-04,US 54666404 P,2004-02-20,NEEDLE GUIDE,"A needle guide 100 for decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical fluid container, by an accessing device 132, such as a syringe with a needle 134 attached to the distal end of the syringe. A device 200 for decreasing the incidence of needle injury to an operator who is accessing the interior of the container by an accessing device 132, such as a syringe with a needle 134 attached to the distal end of the syringe, the device comprising a container, such as a medical fluid container, with an integrated needle guide.",POINT GUARD MEDICAL INC;;FILLER AARON G,FILLER AARON G,,https://lens.org/154-320-077-204-632,Search Report,yes,3,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14;;B65B1/04,,0,0,,,,PENDING
7,US,B1,US 6562318 B1,035-333-220-154-534,2003-05-13,2003,US 35988499 A,1999-07-26,US 35988499 A;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;US 47369795 A,1990-09-14,Drug delivery by axonal transport,"
    A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by agents which undergo neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g., intramuscular injections of a nerve adhesion molecule comprising a physiologically active substance or a diagnostic marker. 
",SYNGENIX LTD,FILLER AARON GERSHON,SIRUS PHARMACEUTICALS LTD (2003-04-14),https://lens.org/035-333-220-154-534,Granted Patent,yes,28,146,6,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K49/1818;;A61K49/1857;;A61K49/1863;;A61K49/1869;;A61K51/1213;;A61K51/1255;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/44;;A61L2300/624;;B82Y5/00;;C12Q1/48;;A61K47/6923;;A61L24/0015;;A61L2300/44;;A61K49/1863;;A61K51/1255;;A61K49/1818;;B82Y5/00;;A61K49/1857;;C12Q1/48;;A61K9/0019;;A61K51/1213;;A61K2121/00;;A61L2300/102;;A61L2300/624;;A61K47/42;;A61K9/0024;;A61K49/1869;;A61K47/6923,A61K9/00;;A61K47/42;;A61K47/48;;A61K49/18;;A61K51/12;;A61L24/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,424/1.29;;424/1.11;;424/1.37,3,3,003-133-811-405-844;;097-900-976-869-019;;061-303-662-868-417,10.1111/j.1471-4159.1980.tb09019.x;;6160208;;3592407;;10.1164/arrd.1987.135.6.1345;;3841102;;10.1007/bf00509197,"Haschke, Richard H. et al. (1980) ""Preparation and Retrograde Axonal Transport of an Antiviral Drug/Horseradish Peroxidase Conjugate"" Journal of Neurochemistry 35(6):1431-1435.;;Gallagher, J.E., G. George, A.R. Brody (1987) ""Sialic acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage membranes"" Am. Rev. Respir. Dis. 135(6):1345-1352 (abstract only).;;Menetrey, D. (1985) ""Retrograde tracing of neural pathways with a protein-gold complex"" Histochemistry 83(5):391-395 (abstract only).",EXPIRED
8,AU,A1,AU 2004/316287 A1,111-033-000-465-306,2005-09-09,2005,AU 2004/316287 A,2004-11-04,US 54666404 P;;US 2004/0037282 W,2004-02-20,Needle guide,,POINT GUARD MEDICAL INC,FILLER AARON G,,https://lens.org/111-033-000-465-306,Patent Application,no,0,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,B65B1/04;;A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14,,0,0,,,,ACTIVE
9,US,A1,US 2005/0187533 A1,180-299-335-155-503,2005-08-25,2005,US 98271304 A,2004-11-04,US 98271304 A;;US 54666404 P,2004-02-20,Needle guide,"A needle guide for decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical fluid container, by an accessing device, such as a syringe with a needle attached to the distal end of the syringe. A device for decreasing the incidence of needle injury to an operator who is accessing the interior of the container by an accessing device, such as a syringe with a needle attached to the distal end of the syringe, the device comprising a container, such as a medical fluid container, with an integrated needle guide. A method of decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical fluid container, by an accessing device, such as a syringe with a needle attached to the distal end of the syringe, the method comprising providing a needle guide according to the present invention, or providing a device comprising a container with an integrated needle guide according to the present invention.",FILLER AARON G.,FILLER AARON G,POINT GUARD MEDICAL INCORPORATED (2005-01-12),https://lens.org/180-299-335-155-503,Patent Application,yes,3,4,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14;;B65B1/04,604/403,0,0,,,,INACTIVE
10,US,B2,US 7059368 B2,030-099-646-617-941,2006-06-13,2006,US 98271304 A,2004-11-04,US 98271304 A;;US 54666404 P,2004-02-20,Needle guide,"A needle guide for decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical fluid container, by an accessing device, such as a syringe with a needle attached to the distal end of the syringe. A device for decreasing the incidence of needle injury to an operator who is accessing the interior of the container by an accessing device, such as a syringe with a needle attached to the distal end of the syringe, the device comprising a container, such as a medical fluid container, with an integrated needle guide. A method of decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical fluid container, by an accessing device, such as a syringe with a needle attached to the distal end of the syringe, the method comprising providing a needle guide according to the present invention, or providing a device comprising a container with an integrated needle guide according to the present invention.",POINT GUARD MEDICAL INC,FILLER AARON G,POINT GUARD MEDICAL INCORPORATED (2005-01-12),https://lens.org/030-099-646-617-941,Granted Patent,yes,3,8,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,B65B1/04;;A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14,141/329;;141/27;;604/416,0,0,,,,INACTIVE
11,EP,A2,EP 1675771 A2,092-586-537-317-461,2006-07-05,2006,EP 04800898 A,2004-11-04,US 2004/0037282 W;;US 54666404 P,2004-02-20,NEEDLE GUIDE,,POINT GUARD MEDICAL INC,FILLER AARON G,,https://lens.org/092-586-537-317-461,Patent Application,yes,0,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,B65B1/04;;A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14,,0,0,,,,DISCONTINUED
12,WO,A3,WO 2001/046895 A3,167-107-184-802-362,2002-07-11,2002,US 0034918 W,2000-12-22,US 17144699 P,1999-12-22,"SYSTEM, METHOD AND ARTICLE OF MANUFACTURE FOR MANAGING A MEDICAL SERVICES NETWORK","A system, method and article of manufacture are provided for managing a medical services network in accordance with an embodiment of the present invention. Diagnostic data about a patient is received from a diagnostic service source. This diagnostic data is obtained by the performance of a diagnostic service on the patient by the diagnostic service source. The diagnostic data is then sent to an interpreter who interprets the processed diagnostic data to generate an interpretation of the diagnostic data. The interpretation is received from the interpreter. Subsequently, the interpretation and/or the diagnostic data may be transmitted to a display via a network. The security of the patient records are optionally protected through password protection and public key encryption in accordance with the Health Information Portability and Accountability Act ('H.I.P.A.').",NEUROGRAFIX;;FILLER AARON G,FILLER AARON G,,https://lens.org/167-107-184-802-362,Search Report,yes,8,0,4,5,0,G16H80/00;;G16H10/60;;G16H15/00;;G16H30/20;;G16H40/67;;G16H10/60;;G16H15/00;;G16H40/67;;G16H80/00;;G16H30/20,G16H30/20;;G16H40/67,,0,0,,,,PENDING
13,WO,A2,WO 1992/004916 A2,153-925-548-068-151,1992-04-02,1992,EP 9101780 W,1991-09-13,GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,PARTICULATE AGENTS,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",ST GEORGE S ENTERPRISES LTD,FILLER AARON GERSHON,,https://lens.org/153-925-548-068-151,Patent Application,yes,0,17,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,0,0,,,,PATENTED
14,EP,A3,EP 0861667 A3,131-460-490-776-837,2001-08-08,2001,EP 97119199 A,1991-09-13,EP 91916129 A;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,Particulate agents,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularised, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON GERSHON,,https://lens.org/131-460-490-776-837,Search Report,yes,4,0,6,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K49/1818;;A61K49/1857;;A61K49/1863;;A61K49/1869;;A61K51/1213;;A61K51/1255;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/44;;A61L2300/624;;B82Y5/00;;C12Q1/48;;A61K47/6923;;A61L24/0015;;A61L2300/44;;A61K49/1863;;A61K51/1255;;A61K49/1818;;B82Y5/00;;A61K49/1857;;C12Q1/48;;A61K9/0019;;A61K51/1213;;A61K2121/00;;A61L2300/102;;A61L2300/624;;A61K47/42;;A61K9/0024;;A61K49/1869;;A61K47/6923,A61K9/00;;A61K47/42;;A61K47/48;;A61K49/18;;A61K51/12;;A61L24/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,2,1,061-303-662-868-417,3841102;;10.1007/bf00509197,"D. MENÉTREY: ""Retrograde tracing of neural pathways with a protein-gold complex."", HISTOCHEMISTRY, vol. 83, 1985, pages 391 - 395, XP002169025;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BECICH, MICHAEL J. ET AL: ""Wheat germ agglutinin is selectively transported to multivesicular bodies"", XP002169026, retrieved from STN Database accession no. 115:180070",DISCONTINUED
15,WO,A2,WO 2005/081708 A2,143-281-817-437-709,2005-09-09,2005,US 2004/0037282 W,2004-11-04,US 54666404 P,2004-02-20,NEEDLE GUIDE,"A needle guide 100 for decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical fluid container, by an accessing device 132, such as a syringe with a needle 134 attached to the distal end of the syringe. A device 200 for decreasing the incidence of needle injury to an operator who is accessing the interior of the container by an accessing device 132, such as a syringe with a needle 134 attached to the distal end of the syringe, the device comprising a container, such as a medical fluid container, with an integrated needle guide.",POINT GUARD MEDICAL INC;;FILLER AARON G,FILLER AARON G,,https://lens.org/143-281-817-437-709,Patent Application,yes,0,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14;;B65B1/04,,0,0,,,,PENDING
16,US,A1,US 2001/0051881 A1,077-629-443-733-046,2001-12-13,2001,US 74642900 A,2000-12-22,US 74642900 A;;US 17144699 P,1999-12-22,"System, method and article of manufacture for managing a medical services network","
   A system, method and article of manufacture are provided for managing a medical services network in accordance with an embodiment of the present invention. Diagnostic data about a patient is received from a diagnostic service source. This diagnostic data is obtained by the performance of a diagnostic service on the patient by the diagnostic service source. The diagnostic data is then sent to an interpreter who interprets the processed diagnostic data to generate an interpretation of the diagnostic data. The interpretation is received from the interpreter. Subsequently, the interpretation and/or the diagnostic data may be transmitted to a display via a network. The security of the patient records are optionally protected through password protection and public key encryption in accordance with the Health Information Portability and Accountability Act (H.I.P.A.) 
",AARON G FILLER,FILLER AARON G,NEUROGRAFIX (2001-06-28),https://lens.org/077-629-443-733-046,Patent Application,yes,8,326,1,5,0,G16H80/00;;G16H10/60;;G16H40/20;;G16H15/00;;G16H30/20;;G16H40/67;;G16H15/00;;G16H80/00;;G16H40/20;;G16H10/60;;G16H40/67;;G16H30/20,G16H10/60;;G16H30/20;;G16H40/67,705/3,0,0,,,,DISCONTINUED
17,EP,A2,EP 0861667 A2,079-593-821-853-768,1998-09-02,1998,EP 97119199 A,1991-09-13,EP 91916129 A;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,Particulate agents,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularised, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON GERSHON,,https://lens.org/079-593-821-853-768,Patent Application,yes,0,19,6,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K49/1818;;A61K49/1857;;A61K49/1863;;A61K49/1869;;A61K51/1213;;A61K51/1255;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/44;;A61L2300/624;;B82Y5/00;;C12Q1/48;;A61K47/6923;;A61L24/0015;;A61L2300/44;;A61K49/1863;;A61K51/1255;;A61K49/1818;;B82Y5/00;;A61K49/1857;;C12Q1/48;;A61K9/0019;;A61K51/1213;;A61K2121/00;;A61L2300/102;;A61L2300/624;;A61K47/42;;A61K9/0024;;A61K49/1869;;A61K47/6923,A61K9/00;;A61K47/42;;A61K47/48;;A61K49/18;;A61K51/12;;A61L24/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,DISCONTINUED
18,WO,A3,WO 1992/004916 A3,030-519-314-962-667,1992-08-20,1992,EP 9101780 W,1991-09-13,GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,PARTICULATE AGENTS,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",ST GEORGE S ENTERPRISES LTD,FILLER AARON GERSHON,,https://lens.org/030-519-314-962-667,Search Report,no,4,0,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,2,2,097-900-976-869-019;;061-303-662-868-417,3592407;;10.1164/arrd.1987.135.6.1345;;3841102;;10.1007/bf00509197,"STN File Server, File Medline, accession no. 87239688, J.E. GALLAGHER et al.: ""Sialic acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage membranes"", & AM. REV. RESPIR. DIS., 135(6), JUNE 1987, 1345-52, see the whole abstract;;STN File Server, File Medline, accession no. 86085167, D. MENETREY: ""Retrograde tracing of neural pathways with a protein-gold complex. I. Light microscopic detection after silver intensification"", & HISTOCHEMISTRY, 83(5), 1985, 391-5, see the whole abstract",PATENTED
19,US,A1,US 2016/0086680 A1,056-280-505-939-162,2016-03-24,2016,US 201514804323 A,2015-07-20,US 201514804323 A;;US 201462026707 P;;US 201462034713 P;;US 201462044395 P;;US 201462050761 P,2014-07-21,"Positron Systems for Energy Storage, Production and Generation","A positron based system is disclosed which extracts electric power from matter-antimatter annihilation reactions between electrons and positrons. In one embodiment, for storage and distribution of electric power, a solar array provides power to a cyclotron that produces the positron emitter 52 Manganese. The positron emitting 52 Mn is incorporated into spinel ferrite nanoparticles capable of suspension in an electrolyte fluid. This liquid pourable energy source is deployed to operate an internal annihilation engine, and to support a system for production of further positrons by a chain reaction pair production method. The various embodiments of this fundamental and new energy system also includes a photonic energy based mechanical piston system containing ferrofluids, an annihilator electrical circuit component and the use of positrons to produce an electron depleted material to generate a static positive electric field device for battery recharging, vehicle levitation, water desalination by deionization and ion plasma rocket engine drive.",FILLER AARON GERSHON,FILLER AARON GERSHON,,https://lens.org/056-280-505-939-162,Patent Application,yes,0,11,1,1,0,G21G1/10;;G21H1/02;;G21H5/00;;Y02E30/10;;G21B1/11;;G21G1/10;;G21H5/00;;G21H1/02,G21B1/11,,0,0,,,,DISCONTINUED
20,US,A1,US 2003/0228260 A1,131-616-324-836-329,2003-12-11,2003,US 34767203 A,2003-01-16,US 34767203 A;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;US 35988499 A;;US 47369795 A;;US 98891993 A,1990-09-14,Particulate agents,"
   A novel means of pharmaceutical delivery for therapy of prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g., intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker. 
",SYNGENIX LTD,FILLER AARON GERSHON,SIRUS PHARMACEUTICALS LTD (2003-04-14),https://lens.org/131-616-324-836-329,Patent Application,yes,22,21,6,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K49/1818;;A61K49/1857;;A61K49/1863;;A61K49/1869;;A61K51/1213;;A61K51/1255;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/44;;A61L2300/624;;B82Y5/00;;C12Q1/48;;A61K47/6923;;A61L24/0015;;A61L2300/44;;A61K49/1863;;A61K51/1255;;A61K49/1818;;B82Y5/00;;A61K49/1857;;C12Q1/48;;A61K9/0019;;A61K51/1213;;A61K2121/00;;A61L2300/102;;A61L2300/624;;A61K47/42;;A61K9/0024;;A61K49/1869;;A61K47/6923,A61K9/00;;A61K47/42;;A61K47/48;;A61K49/18;;A61K51/12;;A61L24/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,424/9.3,0,0,,,,DISCONTINUED
21,EP,A2,EP 1250676 A2,077-408-238-206-256,2002-10-23,2002,EP 00986691 A,2000-12-22,US 0034918 W;;US 17144699 P,1999-12-22,"SYSTEM, METHOD AND ARTICLE OF MANUFACTURE FOR MANAGING A MEDICAL SERVICES NETWORK",,NEUROGRAFIX,FILLER AARON G,,https://lens.org/077-408-238-206-256,Patent Application,yes,0,0,4,5,0,G16H80/00;;G16H10/60;;G16H15/00;;G16H30/20;;G16H40/67;;G16H10/60;;G16H15/00;;G16H40/67;;G16H80/00;;G16H30/20,G16H30/20;;G16H40/67,,0,0,,,,DISCONTINUED
22,AU,A,AU 2001/022882 A,087-273-220-975-708,2001-07-03,2001,AU 2001/022882 A,2000-12-22,US 17144699 P;;US 0034918 W,1999-12-22,"System, method and article of manufacture for managing a medical services network",,NEUROGRAFIX,FILLER AARON G,,https://lens.org/087-273-220-975-708,Patent Application,no,0,0,4,5,0,G16H80/00;;G16H10/60;;G16H15/00;;G16H30/20;;G16H40/67;;G16H10/60;;G16H15/00;;G16H40/67;;G16H80/00;;G16H30/20,G16H30/20;;G16H40/67,,0,0,,,,DISCONTINUED
23,CA,A1,CA 2555196 A1,102-612-082-355-812,2005-09-09,2005,CA 2555196 A,2004-11-04,US 54666404 P;;US 2004/0037282 W,2004-02-20,NEEDLE GUIDE,"A needle guide 100 for decreasing the incidence of needle injury to an operator who is accessing the interior of a container, such as a medical flu id container, by an accessing device 132, such as a syringe with a needle 134 attached to the distal end of the syringe. A device 200 for decreasing the incidence of needle injury to an operator who is accessing the interior of t he container by an accessing device 132, such as a syringe with a needle 134 attached to the distal end of the syringe, the device comprising a container , such as a medical fluid container, with an integrated needle guide.",POINT GUARD MEDICAL INC,FILLER AARON G,,https://lens.org/102-612-082-355-812,Patent Application,no,0,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,B65B1/04;;A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14,,0,0,,,,DISCONTINUED
24,EP,A1,EP 0548157 A1,174-542-281-848-67X,1993-06-30,1993,EP 91916129 A,1991-09-13,EP 9101780 W;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,PARTICULATE AGENTS.,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",ST GEORGE S ENTERPRISES LTD,FILLER AARON GERSHON,SYNGENIX LIMITED (1994-12-21),https://lens.org/174-542-281-848-67X,Patent Application,yes,0,0,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,0,0,,,,EXPIRED
25,AU,A,AU 1991/085142 A,070-644-969-060-609,1992-04-15,1992,AU 1991/085142 A,1991-09-13,GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,PARTICULATE AGENTS,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",ST GEORGE S ENTERPRISES LTD,FILLER AARON GERSHON,,https://lens.org/070-644-969-060-609,Patent Application,no,0,1,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,0,0,,,,PENDING
26,EP,B1,EP 0548157 B1,184-527-283-317-52X,1998-05-20,1998,EP 91916129 A,1991-09-13,EP 9101780 W;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A,1990-09-14,USE OF PARTICULATE AGENTS,"A novel means of pharmaceutical delivery for therapy or prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON GERSHON,SYNGENIX LIMITED (1994-12-21),https://lens.org/184-527-283-317-52X,Granted Patent,yes,4,0,9,68,0,A61K49/1863;;B82Y5/00;;A61K47/6923,A61K47/48;;A61K49/18,,2,0,,,"STN File Server, File Medline, accession no. 87239688; J.E. GALLAGHER et al.: ""Sialic acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage membranes"";;STN File Server, File Medline, accession no. 86085167; D. MENETREY: ""Retrograde tracing of neural pathways with a protein-gold complex. I. Light microscopic detection after silver intensification""",EXPIRED
27,AU,B2,AU 2004/316287 B2,181-911-907-421-470,2007-11-15,2007,AU 2004/316287 A,2004-11-04,US 54666404 P;;US 2004/0037282 W,2004-02-20,Needle guide,,POINT GUARD MEDICAL INCORPORATED,FILLER AARON G,,https://lens.org/181-911-907-421-470,Granted Patent,no,3,0,10,10,0,A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/025;;B01L2200/085;;B01L2300/044;;A61J1/201;;A61B2090/0801;;A61B50/20;;A61J1/2096;;A61M5/321;;B01L3/50825;;B01L2200/085;;B01L2300/044;;B01L2200/025;;A61J1/201;;A61B50/20;;A61B2090/0801,B65B1/04;;A61B19/00;;A61B19/02;;A61J1/00;;A61J1/20;;A61M5/32;;B01L3/14,,0,0,,,,ACTIVE
28,US,A,US 5948384 A,021-568-389-574-444,1999-09-07,1999,US 47369795 A,1995-06-07,US 47369795 A;;GB 9020075 A;;GB 9023580 A;;GB 9027293 A;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;US 98891993 A,1990-09-14,Particulate agents,"A novel means of pharmaceutical delivery for therapy of prophylaxis or to assist surgical or diagnostic operations on the living body is provided by neuronal endocytosis and axonal transport following pharmaceutical administration into vascularized, peripherally innervated tissue, e.g. intramuscular injections of a nerve adhesion molecule in coupled particle comprising a physiologically active substance or a diagnostic marker.",SYNGENIX LTD,FILLER AARON GERSHON,SIRUS PHARMACEUTICALS LTD (2003-04-14),https://lens.org/021-568-389-574-444,Granted Patent,yes,27,48,1,68,0,A61K9/0024;;A61K45/06;;A61K47/42;;A61K49/1863;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/44;;A61L2300/602;;A61L2300/624;;B82Y5/00;;C12Q1/48;;A61K47/6923;;A61K9/0024;;A61K2121/00;;A61L2300/602;;A61K45/06;;A61K49/1863;;A61L2300/44;;C12Q1/48;;A61K51/1213;;A61L2300/624;;A61L24/0015;;B82Y5/00;;A61K47/42;;A61K47/6923,A61K9/00;;A61K47/42;;A61K47/48;;A61K49/18;;A61K51/12;;A61L24/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,424/1.29;;424/1.11;;424/1.37,2,2,097-900-976-869-019;;061-303-662-868-417,3592407;;10.1164/arrd.1987.135.6.1345;;3841102;;10.1007/bf00509197,"Gallagher, J.E., G. George, A.R. Brody (1987) Sialic acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage membranes Am. Rev. Respir. Dis. 135(6):1345 1352 (abstract only).;;Menetrey, D. (1985) Retrograde tracing of neural pathways with a protein gold complex Histochemistry 83(5):391 395 (abstract only).",EXPIRED
29,WO,A2,WO 2001/046895 A2,042-068-139-479-541,2001-06-28,2001,US 0034918 W,2000-12-22,US 17144699 P,1999-12-22,"SYSTEM, METHOD AND ARTICLE OF MANUFACTURE FOR MANAGING A MEDICAL SERVICES NETWORK","A system, method and article of manufacture are provided for managing a medical services network in accordance with an embodiment of the present invention. Diagnostic data about a patient is received from a diagnostic service source. This diagnostic data is obtained by the performance of a diagnostic service on the patient by the diagnostic service source. The diagnostic data is then sent to an interpreter who interprets the processed diagnostic data to generate an interpretation of the diagnostic data. The interpretation is received from the interpreter. Subsequently, the interpretation and/or the diagnostic data may be transmitted to a display via a network. The security of the patient records are optionally protected through password protection and public key encryption in accordance with the Health Information Portability and Accountability Act ('H.I.P.A.').",NEUROGRAFIX;;FILLER AARON G,FILLER AARON G,,https://lens.org/042-068-139-479-541,Patent Application,yes,0,8,4,5,0,G16H80/00;;G16H10/60;;G16H15/00;;G16H30/20;;G16H40/67;;G16H10/60;;G16H15/00;;G16H40/67;;G16H80/00;;G16H30/20,G16H30/20;;G16H40/67,,0,0,,,,PENDING
30,US,B1,US 6560477 B1,099-427-603-868-410,2003-05-06,2003,US 80938301 A,2001-03-15,US 80938301 A;;US 19001500 P,2000-03-17,Joint imaging system utilizing magnetic resonance imaging and associated methods,"
    A method and apparatus utilized for imaging joint regions are disclosed which utilize blood pool contrast agents and particular magnetic resonance imaging parameters, including fat-suppression, to obtain medically useful images of joints. In particular, the methods and apparatus provide medical personnel with accurate and detailed joint images, including joint spaces, which are useful for various therapeutic and diagnostic applications. 
",UNIV CALIFORNIA,FILLER AARON G,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2001-03-06),https://lens.org/099-427-603-868-410,Granted Patent,yes,11,12,2,2,0,A61B5/055;;A61B5/415;;A61B5/416;;A61B5/418;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/415;;A61B5/4504;;A61B5/416;;A61B5/055;;A61B5/418,A61B5/055,600/410;;324/309,4,3,001-602-056-341-563;;060-415-521-791-436;;021-375-344-370-754,3263000;;10.2214/ajr.151.5.1025;;4001160;;10.1088/0031-9155/30/4/008;;10.1148/radiology.153.1.6089263;;6089263,"Atlas et al.; Nov. 1988; STIR MR Imaging of the Orbit; AJR 151:1025-1030.;;Bydder et al.; (1992); Comparison of FLAIR Pulse Sequences with Heavily T2 Weighted SE Sequences in MR Imaging of the Brain; 185 Radiology Supp. 151.;;Haase et al.; Apr. 1985; H NMR chemical shift selective (chess) imaging; Physics in Medicine & Biology, vol. 30, No. 4, pp. 341-344.;;Dixon, T.; Oct. 1984; Simple Proton Spectroscopic Imaging; Radiology, vol. 153, No. 1, pp. 189-194.",EXPIRED
31,DE,D1,DE 69409833 D1,056-394-971-923-374,1998-05-28,1998,DE 69409833 T,1994-06-06,US 7262593 A;;US 9406337 W,1993-06-04,BILDERZEUGUNGSSYSTEM MITTELS MAGNETISCHER RESONANZ ZUR FOKAL-GRAPHISCHEN DARSTELLUNG VON NERVEN,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORG S HOSPITAL MEDICAL SC;;WELLCOME TRUST;;CANCER RES CAMPAIGN TECH,FILLER AARON;;HOWE FRANKLYN,,https://lens.org/056-394-971-923-374,Granted Patent,no,0,0,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,EXPIRED
32,DE,T2,DE 69409833 T2,063-696-204-656-292,1998-09-10,1998,DE 69409833 T,1994-06-06,US 7262593 A;;US 9406337 W,1993-06-04,BILDERZEUGUNGSSYSTEM MITTELS MAGNETISCHER RESONANZ ZUR FOKAL-GRAPHISCHEN DARSTELLUNG VON NERVEN,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORG S HOSPITAL MEDICAL SC;;WELLCOME TRUST;;CANCER RES CAMPAIGN TECH,FILLER AARON;;HOWE FRANKLYN,,https://lens.org/063-696-204-656-292,Granted Patent,no,0,4,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,EXPIRED
33,WO,A1,WO 1994/029741 A1,007-801-920-605-542,1994-12-22,1994,US 9406337 W,1994-06-06,US 7262593 A,1993-06-04,FOCAL NEUROGRAPHIC MAGNETIC RESONANCE IMAGING SYSTEM,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL;;WELLCOME TRUST;;CANCER RES CAMPAIGN TECH;;FILLER AARON G;;HOWE FRANKLYN A,FILLER AARON G;;HOWE FRANKLYN A,,https://lens.org/007-801-920-605-542,Patent Application,yes,6,13,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;A61B5/055;;H01F5/00,,1,0,,,"C. BARLOW ET AL.: ""GRADIENT COIL DESIGN FOR MICROSCOPE IMAGING OF HUMAN EXTREMITIES IN A ONE METER BORE MAGNET"", SOCIETY OF MAGNETIC RESONANCE IN MEDICINE, SEVENTH ANNUAL MEETING AND EXHIBITION, 20 August 1988 (1988-08-20), SAN FRANCISCO, CA , US, pages 132",PATENTED
34,US,A,US 5706813 A,157-536-775-870-239,1998-01-13,1998,US 81994997 A,1997-03-18,US 81994997 A;;GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 25410294 A;;US 7262593 A;;US 2879593 A,1992-03-09,Focal neurographic magnetic resonance imaging system,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32,40,42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32,40,42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL;;CANCER RES CAMPAIGN TECH,FILLER AARON G;;HOWE FRANKLYN A,NEUROGRAFIX (2013-12-27);;WASHINGTON RESEARCH FOUNDATION (2013-12-27);;WASHINGTON UNIVERSITY OF (2008-02-06);;ST. GEORGE'S HOSPITAL MEDICAL SCHOOL (2008-02-01),https://lens.org/157-536-775-870-239,Granted Patent,yes,32,44,1,31,0,G01R33/34;;G01R33/3806;;G01R33/385;;G01R33/56341;;G01R33/3806;;G01R33/385;;G01R33/34;;G01R33/56341,G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563,128/653.5;;324/318,37,31,047-441-178-113-918;;095-082-405-715-310;;118-395-308-985-132;;109-824-751-456-338;;001-815-837-871-11X;;132-379-571-744-093;;049-695-271-769-164;;110-385-436-776-052;;005-927-791-916-360;;035-096-879-934-17X;;065-959-648-708-14X;;045-674-927-978-834;;091-456-657-023-722;;165-381-398-996-042;;060-415-521-791-436;;021-375-344-370-754;;006-380-691-701-274;;027-098-941-179-267;;021-560-933-223-044;;198-623-328-719-396;;035-294-577-047-484;;117-736-089-942-808;;008-139-759-992-031;;068-818-305-455-216;;013-402-901-190-90X;;045-802-438-292-210;;001-602-056-341-563;;030-590-884-187-617;;009-425-940-600-42X;;035-435-582-396-407;;002-374-685-713-715,1461131;;10.1002/mrm.1910280215;;10.1097/00004728-199011000-00001;;2229559;;10.1007/bf00588472;;2259433;;10.1148/radiology.176.2.2367658;;2367658;;1987175;;10.1097/00004728-199101000-00001;;2161612;;pmc8367476;;2370348;;10.1097/00004728-199007000-00003;;1652674;;10.1002/mrm.1910190222;;1943665;;10.1002/mrm.1910200110;;2001526;;1987198;;10.1097/00004728-199101000-00002;;10.1148/radiology.177.2.2217762;;2217762;;10.1002/mrm.1910210117;;1943671;;2054681;;4001160;;10.1088/0031-9155/30/4/008;;10.1148/radiology.153.1.6089263;;6089263;;10.1148/radiology.178.3.1994438;;1994438;;3685357;;10.1148/radiology.165.3.3685357;;2447545;;10.1016/s0030-5898(20)30328-x;;10.1097/00003086-198812000-00009;;2772186;;10.1148/radiology.172.3.2772186;;2541464;;10.1148/radiology.171.3.2541464;;2717746;;10.1148/radiology.171.3.2717746;;pmc8332617;;2549771;;2740501;;10.1148/radiology.172.1.2740501;;1994428;;10.1148/radiology.178.3.1994428;;3263000;;10.2214/ajr.151.5.1025;;1924778;;10.1148/radiology.181.2.1924778;;2266841;;10.1002/mrm.1910160203;;10.1002/mrm.1910180206;;2046514;;1911232,"Howe, F.A., Filler, A.G., Bell, B.A. and Griffiths J.R.; Magnetic Resonance Neurography ; Magnetic Resonance in Medicine 28:328 338 (1992).;;M. Doran et al., Normal and Abnormal White Matter Tracts Shown By MR Imaging Using Directional Diffusion Weighted Sequences, Journal Of Computer Assisted Tomography 14(6): 865 873 (Nov./Dec. 1990).;;M. Doran et al., Magnetic Resonance: Perfusion and Diffusion Imaging, Neuroradiology 32:392 398 (1990).;;M.E. Moseley et al., Diffusion weighted MR Imaging of Anisotropic Water Diffusion in CAT Central Nervous System, Radiology, 176:439 445 (Aug. 1990).;;J.V. Hajnal et al., MR Imaging of Anisotropically Restricted Diffusion of Water in the Nervous System: Technical Anatomic, and Pathologic Considerations, Journal Of Computer Assisted Tomography, 15:1 18 (Jan. 1991).;;M.E. Moseley et al., Diffusion Weighted MR Imaging of Acute Stroke: Correlation with T 2 Weighted and Magnetic Susceptibility Enhanced MR Imaging in Cats, ANJR 11:423 429 (May/Jun. 1990).;;D. Chien et al., MR Diffusion Imaging of the Human Brain, Journal Of Computer Assisted Tomography, 14(4):514 520 (Jul./Aug. 1990).;;G.M. Bydder et al., MR Imaging of Anisotropically Restricted Diffusion of Water in Tumors of the Central Nervous System , Book of Abstracts, Society of Magnetic Resonance in Medicine (1991).;;J.S. Schoeniger et al., NMR Microscopy of Single Neurons Book of Abstracts, Society of Magnetic Resonance in Medicine (1991).;;Douek et al., Myelin Fiber Orientation Color Mapping, Book of Abstracts Society of Magnetic Resonance in Medicine, 919 (1991).;;M.E. Moseley et al., Anisotropy in Diffusion Weighted MRI, Magnetic Resonance In Medicine, 19:321 (1991).;;J.R. MacFall et al., Pre and Postmorten Diffusion Coefficients in Rat Neural and Muscle Tissues, Magnetic Resonance In Medicine 20:89 99 (1991).;;M.E. Moseley et al., Ultrafast Magnetic Resonance Imaging: Diffusion and Perfusion, Canadian Association Of Radiologists, 42(1):31 38 (Feb. 1991).;;D. LeBihan et al., Measuring Random Microscopic Motion of Water in Tissues with MR Imaging: A Cat Brain Study, Journal Of Computer Assisted Tomography, 15(1):19 25 (Jan./Feb. 1991).;;Chenevert et al., Quantitative Diffusion Anisotropy in Rat Gliomas, Book of Abstracts, Society of Magnetic Resonance in Medicine, 787 (1991).;;D. LeBihan, Diffusion/Perfusion MR Imaging of the Brain: From Structure to Function, Radiology, 177:328 329 (1990).;;M.E. Moseley et al., Acute Effects of Exercise on Echo Planar T 2 and Diffusion Weighted MRI of Skeletal Muscle in Volunteers, Book of Abstracts, Society of Magnetic Resonance in Medicine, 108 (1991).;;Neeman et al., A Simple Method for Obtaining Cross Term Free Images for Diffusion Anisotropy Studies in NMR Microimaging, Book of Abstracts, Society of Magnetic Resonance in Medicine (1991).;;J. Guy et al., Fat Suppression MRI; Gd DTPA Enhancement in Experimental Optic Neuritis, Book of Abstracts, Society of Magnetic Resonance in Medicine, 913 (1991).;;G. Sze, Recent Advances in Spinal Magnetic Resonance Imaging, Canadian Association of Radiologists Journal, 42(3):190 198 (Jun. 1991).;;Haase et al., NMR Chemical Shift Selective Imaging , 30 Phys. Med. Biol. 341 344 (1985).;;Dixon et al., Simple Proton Spectroscopic Imaging , 153 Radiology 189 194 (1984).;;Shuman et al., Improved Fat Suppression in STIR MR Imaging: Selecting Inversion Time Through Spectral Display , 178 Radiology 885 889 (1991).;;D.N. Blair et al., Normal Brachial Plexus: MR Imaging, Radiology, 165:763 767 (1987).;;L.M. Fahr et al., Imaging of Peripheral Nerve Lesions, Orthopedic Clinics Of North America, 19(1):27 41 (Jan. 1988).;;B. Roger et al., Imaging of Posttraumatic Brachial Plexus Injury, Clinical Orthopaedics And Related Research, 237:57 61 (Dec. 1988).;;R.R. Tash, M.D., et al., Trigeminal Neuralgia: MR Imaging Features, Radiology 172:767 770 (1989).;;M. Mesgarzadeh et al., Carpal Tunnel: MR Imaging, Part II. Carpal Tunnel Syndrome, Radiology, 171:749 754 (1989).;;M. Mesgarzadeh et al., Carpal Tunnel: MR Imaging, Radiology 171:743 748 (1989).;;D.S. Titelbaum et al., Wallerian Degeneration and Inflammation in Rat Peripheral Nerve Detected by in Vivo MR Imaging, ANJR 10:741 746 (Jul./Aug. 1989).;;M.J. Kuhn et al., Wallerian Degeneration After Cerebral Infarction: Evaluation with Sequential MR Imaging, Radiology 172:179 182 (1989).;;J.K. Kostelic et al., Lumbar Spinal nerves in the Neural Foramen: MR Appearance, Radiology 178:837 839 (1991).;;Atlas et al., STIR MR Imaging of the Orbit, 151 Am. J. Roentgen 151:1025 1030 (1988).;;E.C. Wong et al., High Resolution, Short Echo Time MR Imaging of the Fingers and Wrist with a Local Gradient Coil, Radiology 181:393 397 (1991).;;P.B. Roemer et al., The NMR Phased Array, Magnetic Resonance In Medicine 16:192 225 (1990).;;C.E. Hayes et al., Volume Imaging with MR Phased Arrays, Magnetic Resonance In Medicine 18:309 319 (1991).;;F.G. Shellock et al., Kinematic Magnetic Resonance Imaging of the Joints: Techniques and Clinical Applications, Magnetic Resonance Quarterly, 7(2):104 135 (1991).",EXPIRED
35,EP,B1,EP 0737319 B1,007-267-343-750-864,1998-04-22,1998,EP 94919373 A,1994-06-06,US 9406337 W;;US 7262593 A,1993-06-04,FOCAL NEUROGRAPHIC MAGNETIC RESONANCE IMAGING SYSTEM,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL;;WELLCOME TRUST;;CANCER RES CAMPAIGN TECH,FILLER AARON G;;HOWE FRANKLYN A,UNIVERSITY OF WASHINGTON (2007-10-15),https://lens.org/007-267-343-750-864,Granted Patent,yes,2,0,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,2,2,047-441-178-113-918;;116-896-810-409-686,1461131;;10.1002/mrm.1910280215;;10.1097/00004728-199111000-00044,"Magnetic Resonance in Medicine, vol. 28, 1992, pages 328-338;;Journal of Computer Assisted Tomography, vol. 15, 1991, pages 1-18",EXPIRED
36,AU,A,AU 1994/070540 A,018-867-010-861-062,1995-01-03,1995,AU 1994/070540 A,1994-06-06,US 7262593 A;;US 9406337 W,1993-06-04,Focal neurographic magnetic resonance imaging system,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;CANCER RES CAMPAIGN TECH;;ST GEORGES HOSP MEDICAL SCHOOL;;WELLCOME TRUST,FILLER AARON G;;HOWE FRANKLYN A,,https://lens.org/018-867-010-861-062,Patent Application,no,0,0,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,PENDING
37,CA,C,CA 2163449 C,099-196-073-465-634,2002-11-26,2002,CA 2163449 A,1994-06-06,US 7262593 A;;US 9406337 W,1993-06-04,FOCAL NEUROGRAPHIC MAGNETIC RESONANCE IMAGING SYSTEM,"A focal magnetic resonance imaging system (20) for generating images of neur al structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coi l assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporate d within the splint (28). The splint (28) conforms snugl y to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed wi th respect to the patient's body part. The splint-coil a ssembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is incl uded for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of ope rating the control and analysis system (22) to consisten tly generate images depicting the fascicular structure of nerves (100) by ensuri ng that image gradients (108) are oriented orthogonal to the nerves (100).",CANCER RES CAMPAIGN TECH;;WELLCOME TRUST THE;;ST GEORGES HOSP MEDICAL SCHOOL;;UNIV WASHINGTON,FILLER AARON G;;HOWE FRANKLYN A,,https://lens.org/099-196-073-465-634,Granted Patent,no,0,0,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,EXPIRED
38,DE,T2,DE 69218403 T2,006-489-002-182-018,1997-06-26,1997,DE 69218403 T,1992-01-04,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,FÜR ENDOCYTOSE GEEIGNETE TEILCHEN,,SYNGENIX LTD,FILLER AARON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/006-489-002-182-018,Granted Patent,no,0,0,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
39,CA,A1,CA 2163449 A1,015-232-745-917-84X,1994-12-22,1994,CA 2163449 A,1994-06-06,US 7262593 A;;US 9406337 W,1993-06-04,FOCAL NEUROGRAPHIC MAGNETIC RESONANCE IMAGING SYSTEM,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL;;WELLCOME TRUST THE;;CANCER RES CAMPAIGN TECH,FILLER AARON G;;HOWE FRANKLYN A,,https://lens.org/015-232-745-917-84X,Patent Application,no,0,0,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,EXPIRED
40,US,A1,US 2020/0197351 A1,010-691-998-841-442,2020-06-25,2020,US 201916589042 A,2019-09-30,US 201916589042 A;;US 201862739347 P,2018-10-01,TRIVALENT AND DIVALENT CATIONS AS ADMINISTRABLE AGENTS FOR INCREASED PROCESSIVITY AND IMPROVED FIDELITY OF REVERSE TRANSCRIPTASE IN TELOMERASE AND IN NUCLEIC ACID POLYMERASES,"A novel method of increasing longevity by improving the processivity, fidelity, and activity of the telomerase enzyme is provided by agents which introduce trivalent cations such as scandium 3+ into the nuclei of cells, whereupon there occurs substitution of the trivalent cation into the place of the natural divalent cations such as magnesium or calcium or manganese. This substitution optimizes the adherence of the telomerase enzyme to its nucleic acid template with the result that cellular replicative senescence is delayed and deferred in various cell types. The trivalent cations can be introduced topically, orally as a food additive or supplement, or as a medication for oral, intramuscular, intrathecal or intravenous administration.",FILLER AARON GERSHON;;LEVER ANDREW ML,FILLER AARON GERSHON;;LEVER ANDREW ML,,https://lens.org/010-691-998-841-442,Patent Application,yes,0,0,1,1,0,A61K31/28;;A61K31/28;;A23L33/16;;A23L33/165;;A23V2002/00,A61K31/28;;A23L33/165,,0,0,,,,DISCONTINUED
41,DE,D1,DE 69218403 D1,012-729-134-231-86X,1997-04-24,1997,DE 69218403 T,1992-01-04,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,FÜR ENDOCYTOSE GEEIGNETE TEILCHEN,,SYNGENIX LTD,FILLER AARON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/012-729-134-231-86X,Granted Patent,no,0,0,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
42,US,A,US 5614652 A,125-433-302-630-62X,1997-03-25,1997,US 8778193 A,1993-10-05,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,Particulates,"There is provided a means of cellular level therapy or prophylaxis whereby endocytosable particles are administered so as to emit cytotoxic radiation or to release metal cations having a therapeutic or prophylactic effect, eg. a vital replication suppressing effect, within cells such as macrophages following their uptake by these cells.",SYNGENIX LTD,FILLER AARON G;;LEVER ANDREW M,SYNGENIX LIMITED (1994-07-01);;ST. GEORGE'S ENTERPRISES LIMITED (1994-01-18),https://lens.org/125-433-302-630-62X,Granted Patent,yes,4,29,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,556/136;;556/138,2,1,098-181-526-925-587,1921570,"Speiser, Peter P. (1991) Nanoparticles and Liposomes: A State of the Art Methods and Findings in Experimental and Clinical Pharmacology 13(5):337 342.;;Toshiba Glass Co., Ltd. (1989) Patent Abstracts of Japan 13(496):127 E 843, Abstract No. 1 200605.",EXPIRED
43,WO,A1,WO 1993/005174 A1,151-058-923-560-952,1993-03-18,1993,GB 9201599 W,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A,1991-08-30,NUCLEIC ACID POLYMERASE AMPLIFICATION,Trivalent ion is used to amplify or characterise nucleic acid polymerase activity and optionally also to inhibit nuclease activity.,FILLER AARON GERSHON;;LEVER ANDREW M L,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/151-058-923-560-952,Patent Application,yes,1,1,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,1,1,039-226-569-824-395,580192,"ARZNEIMITTEL FORSCHUNG vol. 28, no. 1, 1 January 1978, AULENDORF, GERMANY pages 21 - 24 SARKANDER, H. I. ET AL. 'MODIFICATION OF RNA SYNTHESIS IN ISOLATED RAT LIVER NUCLEI DURING ANTICOAGULATION TREATMENT WITH LANTHANIDES'",PATENTED
44,CA,A1,CA 2116576 A1,096-815-897-743-335,1993-03-18,1993,CA 2116576 A,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUCLEIC ACID POLYMERASE AMPLIFICATION,2116576 9305174 PCTABS00020 Trivalent ion is used to amplify or characterise nucleic acid polymerase activity and optionally also to inhibit nuclease activity.,,FILLER AARON G;;LEVER ANDREW M L,,https://lens.org/096-815-897-743-335,Patent Application,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
45,EP,B1,EP 0640350 B1,111-072-921-326-919,2002-04-10,2002,EP 94116972 A,1992-09-16,EP 92919662 A;;GB 9119762 A,1991-09-16,Ceramic particles and their preparation,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/111-072-921-326-919,Granted Patent,yes,9,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,1,0,,,"CHEMICAL ABSTRACTS, vol. 104, no. 7, 17 February 1986, Columbus, Ohio, US; abstract no. 48280, PAUL KRONICK ET AL. 'Use of superparamagnetic particles for isolation of cells' & J. BIOCHEM. BIOPHYS. METHODS, vol.12, 1986 pages 73 - 80 'CODEN: JBBMDG;ISSN: 0165-022x'",EXPIRED
46,US,A,US 5554498 A,115-366-057-980-692,1996-09-10,1996,US 20414494 A,1994-02-28,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,Nucleic acid amplification using scandium and lanthanum ions,The subject invention pertains to a method for amplifying the polymerase activity of a nucleic acid polymerase using Group 3 ions. Group 3 ions of the subject invention can also be used to inhibit the enzymatic activity of nucleases. The subject invention further concerns a method for identifying an unknown nucleic acid polymerase or other enzymes in a sample.,SYNGENIX LTD,FILLER AARON G;;LEVER ANDREW M L,SYNGENIX LIMITED (1994-01-21),https://lens.org/115-366-057-980-692,Granted Patent,yes,1,21,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,435/5;;435/6;;435/91.2;;435/810,2,1,039-226-569-824-395,580192,"Erlich A. Henry, PCR Technology Principles and Applications for DNA Amplification, Published 1990 by Stockton Press (U.S.), pp. 1 22.;;Sarkander, H. I., C. G. Uthoff (1978) Modification of RNA Synthesis in Isolated Rat Liver Nuclei during Anticoagulant Treatment with Lanthanides Arzneimittel Forschung 28(1):21 24.",EXPIRED
47,DE,T2,DE 69231178 T2,120-738-002-540-425,2000-11-23,2000,DE 69231178 T,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUKLEINSÄURE-AMPLIFIKATION DURCH POLYMERASE-REAKTION,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/120-738-002-540-425,Granted Patent,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
48,FI,A,FI 940923 A,159-836-303-786-052,1994-02-25,1994,FI 940923 A,1994-02-25,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,Nukleiinihappopolymeraasin tehostaminen,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/159-836-303-786-052,Patent Application,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,PENDING
49,AU,A,AU 1992/024817 A,026-985-776-137-892,1993-04-05,1993,AU 1992/024817 A,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUCLEIC ACID POLYMERASE AMPLIFICATION,,SYNGENIX LTD,AARON GERSHON FILLER;;ANDREW MICHAEL LINDSAY LEVER,,https://lens.org/026-985-776-137-892,Patent Application,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
50,NO,B1,NO 315860 B1,108-964-233-531-113,2003-11-03,2003,NO 940658 A,1994-02-25,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,"Ökt prosessivitet av nukleinsyrepolymeraseaktivitet, samt ett sett",,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/108-964-233-531-113,Granted Patent,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
51,DE,T2,DE 69232547 T2,115-359-763-006-066,2002-11-28,2002,DE 69232547 T,1992-09-16,GB 9119762 A,1991-09-16,Keramische Partikel und Verfahren zur ihren Herstellung,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/115-359-763-006-066,Granted Patent,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
52,US,B2,US 6919067 B2,035-565-226-623-189,2005-07-19,2005,US 1516201 A,2001-12-11,US 1516201 A;;EP 9101780 W;;GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A;;GB 9501330 W;;US 77673797 A;;US 98891993 A;;US 47369795 A,1991-09-13,Compositions comprising a tissue glue and therapeutic agents,"The present invention concerns compositions comprising a radiotherapeutic agent, or an agent which can be converted to a radiotherapeutic, and a tissue glue. The compositions of the present invention are particularly useful for providing local radiotherapy. The present invention also concerns methods of using the compositions of the invention, particularly for radiotherapy.",SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SIRUS PHARMACEUTICALS LTD (2004-06-07);;MOLECULAR SYNTHETICS LIMITED (2004-02-09),https://lens.org/035-565-226-623-189,Granted Patent,yes,40,17,3,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44;;A61K9/0024;;A61L2300/414;;A61K9/0019;;A61K2121/00;;A61K47/42;;A61L2300/44;;A61L24/0015;;A61L2300/102;;A61K51/1213,A61K9/00;;A61K47/42;;A61K51/12;;A61L24/00,424/1.29;;424/1.25;;424/1.11;;424/1.49;;424/1.33,7,5,052-252-706-129-576;;052-252-706-129-576;;097-900-976-869-019;;061-303-662-868-417;;003-133-811-405-844,10.1016/s0001-2998(89)80013-3;;2503873;;10.1016/s0001-2998(89)80013-3;;2503873;;3592407;;10.1164/arrd.1987.135.6.1345;;3841102;;10.1007/bf00509197;;10.1111/j.1471-4159.1980.tb09019.x;;6160208,"Bhargava et al. ""Labeling of Monoclonal antibodies with radionuclides,"" 1989, Seminars in Nuclear Medicine, vol. 19, pp. 187-201.;;Bhargava et al. ""Labeling Monoclonal Antibodies with Radionuclides"" Seminars in Nuclear Medicine, Jul. 1989, pp. 187-201, vol. 19, No. 3.;;Database WPI, Week 9306, Derwent Publications Ltd., London, GB; AN 93-049554 (06).;;World Patent Index, abstract of J P-A-500097, Jan. 8, 1993.;;Gallagher, J.E. et al. ""Sialic Acid Mediates the Initial Binding of Positively Charged Inorganic Oarticles to Alveolar Macrophage Membranes"" Am. Rev. Respir. Dis., 1987, pp. 1345-1352, vol. 135, No. 6 (abstract only).;;Menetrey, D. ""Retrograde Tracing of Neural Pathways with a Protein-Gold Complex"" Histochemistry, 1985, pp. 391-395, vol. 83, No. 5 (abstract only).;;Haschke, Richard H. et al. ""Preparation and Retrograde Axonal Transport of an Antiviral Drug/Horseradish Peroxidase Conjugate"" Journal of Neurochemistry, 1980, pp. 1431-1435, vol. 35, No. 6.",EXPIRED
53,AU,B2,AU 670755 B2,003-540-477-030-810,1996-08-01,1996,AU 1992/024817 A,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,Nucleic acid polymerase amplification,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/003-540-477-030-810,Granted Patent,no,1,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
54,AU,A,AU 1992/025679 A,070-856-680-040-601,1993-04-27,1993,AU 1992/025679 A,1992-09-16,GB 9119762 A;;GB 9201703 W,1991-09-16,SYNTHETIC TRANSFECTION VECTORS,,SYNGENIX LTD,AARON GERSHON FILLER;;ANDREW MICHAEL LINDSAY LEVER,,https://lens.org/070-856-680-040-601,Patent Application,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
55,FI,A0,FI 940923 A0,081-019-013-826-812,1994-02-25,1994,FI 940923 A,1994-02-25,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,Nukleiinihappopolymeraasin tehostaminen,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/081-019-013-826-812,Patent Application,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,PENDING
56,WO,A1,WO 1993/005815 A1,013-527-585-286-609,1993-04-01,1993,GB 9201703 W,1992-09-16,GB 9119762 A,1991-09-16,SYNTHETIC TRANSFECTION VECTORS,"A physiologically-acceptable agent, adapted to deliver a nucleic acid to a cell, comprises inorganic particles to which are bound a cell-binding component and the nucleic acid. The inorganic particles may be biodegradable.",FILLER AARON GERSHON;;LEVER ANDREW M L,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/013-527-585-286-609,Patent Application,yes,8,14,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,PENDING
57,CA,A1,CA 2099869 A1,031-207-629-060-805,1992-07-08,1992,CA 2099869 A,1992-01-04,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A,1991-01-07,PARTICULATES,"2099869 9211846 PCTABS00014 There is provided a means of cellular level therapy or prophylaxis whereby endocytosable particles are administered so as to emit cytotoxic radiation or to release metal cations having a therapeutic or prophylactic effect, eg. a viral replication suppressing effect, within cells such as macrophages following their uptake by these cells.",ST GEORGE S ENTERPRISES LTD;;SYNGENIX LTD,FILLER AARON G;;LEVER ANDREW M L,,https://lens.org/031-207-629-060-805,Patent Application,no,0,0,2,68,0,,A61K9/16;;A61K33/00;;A61K47/48,,0,0,,,,EXPIRED
58,EP,B1,EP 0601010 B1,081-231-608-674-086,2000-06-14,2000,EP 92918221 A,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUCLEIC ACID POLYMERASE AMPLIFICATION,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SYNGENIX LIMITED (1994-11-17),https://lens.org/081-231-608-674-086,Granted Patent,yes,1,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,1,0,,,"ARZNEIMITTEL FORSCHUNG vol. 28, no. 1, 1 January 1978, AULENDORF, GERMANY pages 21 - 24 SARKANDER, H. I. ET AL. 'MODIFICATION OF RNA SYNTHESIS IN ISOLATED RAT LIVER NUCLEI DURING ANTICOAGULATION TREATMENT WITH LANTHANIDES'",EXPIRED
59,AU,A,AU 1992/011536 A,082-356-976-655-343,1992-08-17,1992,AU 1992/011536 A,1992-01-04,GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,PARTICULATES,,ST GEORGES ENTERPRISES LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/082-356-976-655-343,Patent Application,no,0,0,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,PENDING
60,WO,A1,WO 1992/011846 A1,093-810-173-647-071,1992-07-23,1992,EP 9200021 W,1992-01-04,GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,PARTICULATES,"There is provided a means of cellular level therapy or prophylaxis whereby endocytosable particles are administered so as to emit cytotoxic radiation or to release metal cations having a therapeutic or prophylactic effect, eg. a viral replication suppressing effect, within cells such as macrophages following their uptake by these cells.",ST GEORGE S ENTERPRISES LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/093-810-173-647-071,Patent Application,yes,5,15,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,1,1,098-181-526-925-587,1921570,"Methods and Findings in Experimental and Clinical Pharmacology, vol. 13, no. 5, 1991, P.P. SPEISER: ""Nanoparticles and liposomes: A state of the art"", pages 337-342, see whole article",PATENTED
61,EP,A3,EP 0640350 A3,127-703-930-667-52X,1995-12-13,1995,EP 94116972 A,1992-09-16,EP 92919662 A;;GB 9119762 A,1991-09-16,Ceramic particles and their preparation.,"Ferrite particles obtainable by coprecipitation of ferrous and ferric salts from aqueous solution, are free of hydrous oxides chelatable with EDTA. They are thus particularly pure, and suitable as vectors for therapeutic or diagnostic use.",SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/127-703-930-667-52X,Search Report,yes,9,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,1,0,,,"CHEMICAL ABSTRACTS, vol. 104, no. 7, 17 February 1986, Columbus, Ohio, US; abstract no. 48280, PAUL KRONICK ET AL. 'Use of superparamagnetic particles for isolation of cells' & J. BIOCHEM. BIOPHYS. METHODS, vol.12, 1986 pages 73 - 80 'CODEN: JBBMDG;ISSN: 0165-022x'",EXPIRED
62,WO,A1,WO 1996/003112 A1,127-107-477-113-658,1996-02-08,1996,GB 9501330 W,1995-06-07,GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A;;US 98891993 A,1993-05-04,COMPOSITIONS COMPRISING A TISSUE GLUE AND THERAPEUTIC AGENTS,"Especially for local radiotherapy, a therapeutic agent is applied with a tissue glue.",SYNGENIX LTD;;FILLER AARON GERSHON;;LEVER ANDREW M L,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/127-107-477-113-658,Patent Application,yes,4,12,5,68,0,A61K9/0024;;A61K9/0019;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44,A61K9/00;;A61K9/20;;A61K47/32;;A61K47/42;;A61K51/12;;A61L24/00,,1,0,,,"DATABASE WPI Week 9306, Derwent World Patents Index; AN 93-049554 (06)",PATENTED
63,US,A1,US 2005/0002860 A1,087-665-659-241-463,2005-01-06,2005,US 91069604 A,2004-08-02,US 91069604 A;;GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A;;US 1516201 A;;US 77673797 A;;US 47369795 A;;US 98891993 A,1993-05-04,Compositions comprising a tissue glue and therapeutic agents,"The present invention concerns compositions comprising a radiotherapeutic agent, or an agent which can be converted to a radiotherapeutic, and a tissue glue. The compositions of the present invention are particularly useful for providing local radiotherapy. The present invention also concerns methods of using the compositions of the invention, particularly for radiotherapy.",FILLER AARON GERSHON;;LINDSAY LEVER ANDREW MICHAEL,FILLER AARON GERSHON;;LINDSAY LEVER ANDREW MICHAEL,,https://lens.org/087-665-659-241-463,Patent Application,yes,26,4,3,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44;;A61K9/0024;;A61L2300/414;;A61K9/0019;;A61K2121/00;;A61K47/42;;A61L2300/44;;A61L24/0015;;A61L2300/102;;A61K51/1213,A61K9/00;;A61K47/42;;A61K51/12;;A61L24/00,424/1.11,0,0,,,,DISCONTINUED
64,EP,A2,EP 0640350 A2,116-294-711-507-477,1995-03-01,1995,EP 94116972 A,1992-09-16,EP 92919662 A;;GB 9119762 A,1991-09-16,Ceramic particles and their preparation.,"Ferrite particles obtainable by coprecipitation of ferrous and ferric salts from aqueous solution, are free of hydrous oxides chelatable with EDTA. They are thus particularly pure, and suitable as vectors for therapeutic or diagnostic use.",SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/116-294-711-507-477,Patent Application,yes,0,1,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
65,US,A,US 6153598 A,166-922-866-234-838,2000-11-28,2000,US 6214598 A,1998-04-17,US 6214598 A;;GB 9201703 W;;GB 9119762 A;;US 58319596 A;;US 21104194 A,1991-09-16,Synthetic transfection vectors,"An inorganic particle, to which is bonded a cell binding component and a nucleic acid, is provided for delivery of a nucleic acid to a cell. The disclosed particle acts as a synthetic vector for achieving efficient transfection of associated nucleic acid into a cell.",SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SYNGENIX LIMITED (1994-01-21),https://lens.org/166-922-866-234-838,Granted Patent,yes,9,9,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,514/44;;424/490;;424/491;;424/493,4,3,014-560-945-633-768;;058-429-436-163-000;;008-845-504-975-326,1352882;;10.1073/pnas.89.13.6094;;pmc49444;;3049582;;10.1016/s0021-9258(18)68081-0;;10.1021/bi00435a043;;2752000,"Cotten, M. et al. (1992) High efficiency receptor mediated delivery of small and large 48 kilobase gene constructs using the endosome disruption activity of defective or chemically inactivated adenovirus particles. Proc. Natl. Acad. Sci. USA 89: 6094 6098.;;Audesirk, G., Audesirk, T. (1986) Biology: Life on Earth. New York, MacMillan Publishing Company, pp. 66 67.;;Wu, G.Y., Wu, C.H. (1988) Receptor mediated Gene Delivery and Expression in Vivo. The Journal of Biological Chemistry 263(29): 14621 14624.;;Walker, P.R. et al. (1989) Effects of Aluminum and Other Cations on the Structure of Brain and Liver Chromatin. Biochemistry 28: 3911 3915.",EXPIRED
66,CA,A1,CA 2119145 A1,168-964-346-042-347,1993-04-01,1993,CA 2119145 A,1992-09-16,GB 9119762 A;;GB 9201703 W,1991-09-16,FERRITE PARTICLES AND THERAPEUTIC AND DIAGNOSTIC USES THEREFORE,"2119145 9305815 PCTABS00021 A physiologically-acceptable agent, adapted to deliver a nucleic acid to a cell, comprises inorganic particles to which are bound a cell-binding component and the nucleic acid. The inorganic particles may be biodegradable.",FILLER AARON G;;LEVER ANDREW M L,FILLER AARON G;;LEVER ANDREW M L,,https://lens.org/168-964-346-042-347,Patent Application,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
67,US,B2,US 6809082 B2,184-807-822-940-262,2004-10-26,2004,US 97177601 A,2001-10-04,US 97177601 A;;GB 9119762 A;;US 70238100 A;;US 6214598 A;;US 58319596 A;;US 21104194 A,1991-09-16,Synthetic transfection vectors,"
    An inorganic particle, to which is bonded a cell binding component and a nucleic acid, is provided for delivery of a nucleic acid to a cell. The disclosed particle acts as a synthetic vector for achieving efficient transfection of associated nucleic acid into a cell. 
",MOLECULAR SYNTHETICS LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SIRUS PHARMACEUTICALS LTD (2004-06-07);;MOLECULAR SYNTHETICS LIMITED (2004-02-09),https://lens.org/184-807-822-940-262,Granted Patent,yes,13,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,514/44;;435/320.1;;424/489;;424/490;;424/493;;424/497;;424/491,8,6,015-259-510-956-158;;009-416-320-508-847;;019-810-335-711-889;;014-560-945-633-768;;058-429-436-163-000;;008-845-504-975-326,10.1016/0165-022x(86)90052-7;;2418094;;9305836;;10.1038/38410;;9579858;;1352882;;10.1073/pnas.89.13.6094;;pmc49444;;3049582;;10.1016/s0021-9258(18)68081-0;;10.1021/bi00435a043;;2752000,"Chemical Abstracts, No. 48280, Columbus, Ohio; Kronick, P. and Gilpin, R.W. ""Use of superparamagnetic particles for isolation of cells,"" J. Biochem. Biophys. Methods (1986), pp. 254, vol. 104, No. 7.;;Kronick, P. and Gilpin, R.W. ""Use of superparamagnetic particles for isolation of cells,"" J. Biochem. Biophys. Methods (1986), pp. 73-80, vol. 12; Elsevier Science Publishers B.V.;;Verma, I.M. et al. ""Gene Therapy-Promises, Problems and Prospects"" Nature, 1997, pp. 239-242, vol. 389.;;Anderson, W. F. ""Human Gene Therapy"" Nature, 1998, pp. 25-30, vol. 392.;;Cotten, M. et al. ""High-Efficiency Receptor-Mediated Delivery of Small and Large 48 Kilobase Gene Constructs Using the Endosome-Disruption Activity of Defective or Chemically Inactivated Adenovirus Particles"" Proc. Natl. Acad. Sci. USA, 1992, pp. 6094-6098, vol. 89.;;Audesirk, G. et al. Biology: Life on Earth, 1986, pp. 66-67, MacMillan Publishing Company, New York.;;Wu, G.Y. et al. ""Receptor-Mediated Gene Delivery and Expression in Vivo"" The Journal of Biological Chemistry, 1988, pp. 14621-14624, vol. 263, No. 29.;;Walker, P.R. et al. ""Effects of Aluminum and Other Cations on the Structure of Brain and Liver Chromatin"" Biochemistry, 1989, pp. 3911-3915, vol. 28.",EXPIRED
68,NO,D0,NO 940658 D0,185-297-178-841-616,1994-02-25,1994,NO 940658 A,1994-02-25,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,Nukleinsyre-polymerase-forökning,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/185-297-178-841-616,Patent Application,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
69,ES,T3,ES 2176216 T3,134-611-005-521-756,2002-12-01,2002,ES 94116972 T,1992-09-16,GB 9119762 A,1991-09-16,PARTICULAS DE CERAMICA Y SU PREPARACION.,"LAS PARTICULAS DE FERRITA QUE OBTIENEN MEDIANTE LA COPRECIPITACION DE SALES FERROSAS Y FERRICAS DE UNA SOLUCION ACUOSA, NO TIENEN OXIDOS HIDRICOS QUE SE PUEDAN QUELAR CON EDTA. POR TANTO SON PARTICULARMENTE PURAS Y ADECUADAS COMO VECTORES DE USO TERAPEUTICO O DE DIAGNOSTICO.",SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/134-611-005-521-756,Granted Patent,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
70,CA,C,CA 2116576 C,157-520-567-520-289,2002-11-12,2002,CA 2116576 A,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUCLEIC ACID POLYMERASE AMPLIFICATION,Trivalent ion is used to amplify or characterise nucleic acid polymerase activity and optionally also to inhibit nuclease ac- tivity.,,FILLER AARON G;;LEVER ANDREW M L,,https://lens.org/157-520-567-520-289,Granted Patent,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
71,EP,A1,EP 0610232 A1,131-663-340-684-179,1994-08-17,1994,EP 92919662 A,1992-09-16,GB 9119762 A;;GB 9201703 W,1991-09-16,SYNTHETIC TRANSFECTION VECTORS.,"On décrit un agent physiologiquement tolérable, adapté pour fournir un acide nucléique à une cellule et comprenant des particules inorganiques auxquelles sont liés un composant de liaison de cellule ainsi que l'acide nucléique. Les particules inorganiques peuvent être biodégradables.",SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SYNGENIX LIMITED (1994-11-17),https://lens.org/131-663-340-684-179,Patent Application,yes,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,1,0,,,See references of WO 9305815A1,DISCONTINUED
72,NO,L,NO 940658 L,012-036-683-232-61X,1994-02-25,1994,NO 940658 A,1994-02-25,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,Nukleinsyre-polymerase-forökning,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/012-036-683-232-61X,Abstract,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
73,US,A1,US 2002/0168319 A1,051-240-586-610-124,2002-11-14,2002,US 1516201 A,2001-12-11,US 1516201 A;;EP 9101780 W;;GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A;;GB 9501330 W;;US 77673797 A;;US 98891993 A;;US 47369795 A,1991-09-13,Compositions comprising a tissue glue and therapeutic agents,"
   The present invention concerns compositions comprising a radiotherapeutic agent, or an agent which can be converted to a radiotherapeutic, and a tissue glue. The compositions of the present invention are particularly useful for providing local radiotherapy. The present invention also concerns methods of using the compositions of the invention, particularly for radiotherapy. 
",FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SIRUS PHARMACEUTICALS LTD (2004-06-07);;MOLECULAR SYNTHETICS LIMITED (2004-02-09),https://lens.org/051-240-586-610-124,Patent Application,yes,0,29,3,68,0,A61K9/0019;;A61K9/0024;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44;;A61K9/0024;;A61L2300/414;;A61K9/0019;;A61K2121/00;;A61K47/42;;A61L2300/44;;A61L24/0015;;A61L2300/102;;A61K51/1213,A61K9/00;;A61K47/42;;A61K51/12;;A61L24/00,424/1.69,0,0,,,,EXPIRED
74,CA,C,CA 2119145 C,064-918-656-043-70X,2003-11-25,2003,CA 2119145 A,1992-09-16,GB 9119762 A;;GB 9201703 W,1991-09-16,FERRITE PARTICLES AND THERAPEUTIC AND DIAGNOSTIC USES THEREFORE,Ferrite particles obtained by coprecipitation of ferrous and ferric salts from aqueous solution are free of hydrous oxides chelatable with EDTA and are coated with a biologically tolerable polymer. Also disclosed is a process for preparing such particles.,FILLER AARON G;;LEVER ANDREW M L,FILLER AARON G;;LEVER ANDREW M L,,https://lens.org/064-918-656-043-70X,Granted Patent,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
75,DE,T2,DE 69531869 T2,084-312-314-889-51X,2004-07-22,2004,DE 69531869 T,1995-06-07,GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A;;GB 9501330 W,1994-07-21,ZUSAMMENSETZUNG ENTHALTEND EINEN GEWEBEKLEBSTOFF UND EIN IMMOBILISIERTES THERAPEUTISCHES WIRKSTOFFTEILCHEN,,SIRUS PHARMACEUTICALS LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/084-312-314-889-51X,Granted Patent,no,0,0,5,68,0,A61K9/0024;;A61K9/0019;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44,A61K9/00;;A61K9/20;;A61K47/32;;A61K47/42;;A61K51/12;;A61L24/00,,0,0,,,,EXPIRED
76,DE,D1,DE 69232547 D1,090-060-396-825-489,2002-05-16,2002,DE 69232547 T,1992-09-16,GB 9119762 A,1991-09-16,Keramische Partikel und Verfahren zur ihren Herstellung,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/090-060-396-825-489,Granted Patent,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
77,EP,B1,EP 0804153 B1,171-829-019-114-24X,2003-10-01,2003,EP 95921073 A,1995-06-07,GB 9501330 W;;GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A,1994-07-21,COMPOSITION COMPRISING A TISSUE GLUE AND AN IMMOBILISED THERAPEUTIC PARTICLE,,SIRUS PHARMACEUTICALS LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SIRUS PHARMACEUTICALS LTD. (2003-07-23),https://lens.org/171-829-019-114-24X,Granted Patent,yes,4,0,5,68,0,A61K9/0024;;A61K9/0019;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44,A61K9/00;;A61K9/20;;A61K47/32;;A61K47/42;;A61K51/12;;A61L24/00,,1,0,,,"DATABASE WPI Week 9306, Derwent Publications Ltd., London, GB; AN 93-049554 (06) & JP,A,05 000 970 (SUMITOMO CEMENT CO.) 8 January 1993",EXPIRED
78,EP,A1,EP 0804153 A1,170-465-275-825-365,1997-11-05,1997,EP 95921073 A,1995-06-07,GB 9501330 W;;GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A,1994-07-21,COMPOSITIONS COMPRISING A TISSUE GLUE AND THERAPEUTIC AGENTS,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SIRUS PHARMACEUTICALS LTD. (2003-07-23),https://lens.org/170-465-275-825-365,Patent Application,yes,0,0,5,68,0,A61K9/0024;;A61K9/0019;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44,A61K9/00;;A61K9/20;;A61K47/32;;A61K47/42;;A61K51/12;;A61L24/00,,1,0,,,See references of WO 9603112A1,EXPIRED
79,CA,C,CA 2099869 C,103-457-588-496-54X,2005-03-29,2005,CA 2099869 A,1992-01-04,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A,1991-01-07,PARTICULATES,"There is provided a means of cellular level therapy or prophylaxis whereby endocytosable particles are administered so as to emit cytotoxic radiation onto release metal cations haying a therapeutic or prophylactic effect, eg. a viral replication suppressing effect, within cells such as macrophages following their uptake by these cells.",ST GEORGES ENTPR LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/103-457-588-496-54X,Granted Patent,no,0,0,2,68,0,,A61K9/16;;A61K33/00;;A61K47/48,,0,0,,,,EXPIRED
80,EP,A1,EP 0601010 A1,127-874-342-578-287,1994-06-15,1994,EP 92918221 A,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUCLEIC ACID POLYMERASE AMPLIFICATION.,Un ion trivalent permet d'amplifier ou de caractériser l'activité polymérase propre à l'acide nucléique et aussi d'inhiber éventuellement l'activité nucléase.,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SYNGENIX LIMITED (1994-11-17),https://lens.org/127-874-342-578-287,Patent Application,yes,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
81,DE,D1,DE 69231178 D1,174-629-058-513-596,2000-07-20,2000,DE 69231178 T,1992-09-01,GB 9118676 A;;GB 9123677 A;;GB 9205470 A;;GB 9206402 A;;GB 9201599 W,1991-08-30,NUKLEINSÄURE-AMPLIFIKATION DURCH POLYMERASE-REAKTION,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/174-629-058-513-596,Granted Patent,no,0,0,17,68,0,B82Y5/00;;C12Q1/48;;C12Q1/6846;;Y10S435/81;;B82Y5/00;;C12Q1/6846;;C12Q1/48;;Y10S435/81,C12Q1/48;;C12Q1/68;;C12Q1/70,,0,0,,,,EXPIRED
82,AU,B2,AU 669128 B2,193-254-576-300-065,1996-05-30,1996,AU 1992/025679 A,1992-09-16,GB 9119762 A;;GB 9201703 W,1991-09-16,Synthetic transfection vectors,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/193-254-576-300-065,Granted Patent,no,3,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
83,US,A1,US 2002/0123478 A1,060-468-835-480-621,2002-09-05,2002,US 97177601 A,2001-10-04,US 97177601 A;;GB 9119762 A;;US 70238100 A;;US 6214598 A;;US 58319596 A;;US 21104194 A,1991-09-16,Synthetic transfection vectors,"
   An inorganic particle, to which is bonded a cell binding component and a nucleic acid, is provided for delivery of a nucleic acid to a cell. The disclosed particle acts as a synthetic vector for achieving efficient transfection of associated nucleic acid into a cell. 
",FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,SIRUS PHARMACEUTICALS LTD (2004-06-07);;MOLECULAR SYNTHETICS LIMITED (2004-02-09),https://lens.org/060-468-835-480-621,Patent Application,yes,0,1,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,514/44;;424/493,0,0,,,,EXPIRED
84,DE,D1,DE 69531869 D1,120-737-363-027-497,2003-11-06,2003,DE 69531869 T,1995-06-07,GB 9414684 A;;GB 9415405 A;;GB 9502246 A;;GB 9503357 A;;GB 9501330 W,1994-07-21,ZUSAMMENSETZUNG ENTHALTEND EINEN GEWEBEKLEBSTOFF UND EIN IMMOBILISIERTES THERAPEUTISCHES WIRKSTOFFTEILCHEN,,SIRUS PHARMACEUTICALS LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/120-737-363-027-497,Granted Patent,no,0,0,5,68,0,A61K9/0024;;A61K9/0019;;A61K47/42;;A61K51/1213;;A61K2121/00;;A61L24/0015;;A61L2300/102;;A61L2300/414;;A61L2300/44,A61K9/00;;A61K9/20;;A61K47/32;;A61K47/42;;A61K51/12;;A61L24/00,,0,0,,,,EXPIRED
85,DK,T3,DK 0640350 T3,135-087-592-083-583,2002-08-05,2002,DK 94116972 T,1992-09-16,GB 9119762 A,1991-09-16,Keramiske partikler og fremstilling deraf,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY,,https://lens.org/135-087-592-083-583,Granted Patent,no,0,0,19,19,0,A61K49/0002;;A61K49/0002;;A61K9/1676;;A61K9/1676;;A61K47/6923;;A61K47/6923;;A61K47/6925;;A61K47/6925;;A61K48/00;;A61K48/00,A61K31/70;;A61K9/16;;A61K47/48;;A61K48/00;;A61K49/00,,0,0,,,,EXPIRED
86,DE,T2,DE 69325508 T2,137-151-105-387-392,2000-01-27,2000,DE 69325508 T,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,NEUROGRAPHISCHE ABBILDUNGSVERFAHREN UND DIFFUSIONS-ANISTROPIE,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON SEATTLE;;ST GEORG S HOSPITAL MEDICAL SC,FILLER AARON;;HOWE FRANKLYN;;TSURUDA JAY;;RICHARDS TODD,,https://lens.org/137-151-105-387-392,Granted Patent,no,0,2,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
87,EP,B1,EP 0566590 B1,105-761-697-829-584,1997-03-19,1997,EP 92901269 A,1992-01-04,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,PARTICULATES,,SYNGENIX LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY D,SYNGENIX LIMITED (1994-12-07),https://lens.org/105-761-697-829-584,Granted Patent,yes,5,0,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,1,0,,,"Methods and Findings in Experimental and Clinical Pharmacology, vol. 13, no. 5, 1991, P.P. SPEISER: ""Nanoparticles and liposomes: A state of the art"", pages 337-342, see whole article",EXPIRED
88,AT,T1,AT E165449 T1,194-435-846-583-886,1998-05-15,1998,AT 94919373 T,1994-06-06,US 7262593 A,1993-06-04,BILDERZEUGUNGSSYSTEM MITTELS MAGNETISCHER RESONANZ ZUR FOKAL-GRAPHISCHEN DARSTELLUNG VON NERVEN,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL;;WELLCOME TRUST;;CANCER RES CAMPAIGN TECH,FILLER AARON G ATKINSON MOLREY;;HOWE FRANKLYN A,,https://lens.org/194-435-846-583-886,Granted Patent,no,0,0,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,DISCONTINUED
89,EP,A1,EP 0737319 A1,079-479-260-692-204,1996-10-16,1996,EP 94919373 A,1994-06-06,US 9406337 W;;US 7262593 A,1993-06-04,FOCAL NEUROGRAPHIC MAGNETIC RESONANCE IMAGING SYSTEM,"A focal magnetic resonance imaging system (20) for generating images of neural structures such as nerves. The system (20) includes a control and analysis system (22), a polarizing system (24), and splint-coil assembly (26). The splint-coil assembly (26) includes a splint (28) and various magnetic and electromagnetic coils (32, 40, 42) incorporated within the splint (28). The splint (28) conforms snugly to a patient's body part, e.g., limb, so that the coils (32, 40, 42) are fixed with respect to the patient's body part. The splint-coil assembly (26) can be positioned independently of a main field generated by the polarizing system (24), and a stabilization apparatus (156) is included for adjustably securing the position of the splint-coil assembly (26) during imaging. A focal magnet assembly (60) that can serve as the polarizing system (24) is also provided. Further provided is a method of operating the control and analysis system (22) to consistently generate images depicting the fascicular structure of nerves (100) by ensuring that image gradients (108) are oriented orthogonal to the nerves (100).",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL;;WELLCOME TRUST;;CANCER RES CAMPAIGN TECH,FILLER AARON G ATKINSON MOLREY;;HOWE FRANKLYN A,UNIVERSITY OF WASHINGTON (2007-10-15),https://lens.org/079-479-260-692-204,Patent Application,yes,0,1,10,31,0,G01R33/34;;G01R33/34084;;G01R33/3806;;G01R33/385;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/38;;G01R33/385;;G01R33/563;;H01F5/00,,0,0,,,,EXPIRED
90,EP,A1,EP 0566590 A1,150-531-247-310-636,1993-10-27,1993,EP 92901269 A,1992-01-04,EP 9200021 W;;GB 9100233 A;;GB 9100981 A;;GB 9102146 A;;GB 9110876 A;;GB 9116373 A;;GB 9117851 A;;GB 9118676 A;;GB 9119665 A,1991-01-07,PARTICULATES.,"Thérapie ou prophylaxie au niveau des cellules, comprenant l'administration de particules aptes à subir une endocytase afin qu'elles émettent un rayonnement cytotoxique ou qu'elles dégagent des cations métalliques présentant un effet thérapeutique ou prophylactique tel qu'un effet de suppression de la réplication virale, à l'intérieur de cellules telles que les macrophages et après leur absorption par ces cellules.",ST GEORGE S ENTERPRISES LTD,FILLER AARON GERSHON;;LEVER ANDREW MICHAEL LINDSAY D,SYNGENIX LIMITED (1994-12-07),https://lens.org/150-531-247-310-636,Patent Application,yes,0,0,8,68,0,A61K9/5123;;A61K9/5123;;A61K9/5161;;A61K9/5161;;A61K47/6923;;A61K47/6923;;A61K49/1818;;A61K49/1818;;A61K49/1863;;A61K49/1863;;A61K49/1866;;A61K49/1866;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/48,A61K9/14;;A61K9/51;;A61K33/00;;A61K33/24;;A61K47/48;;A61K49/18;;A61K51/00;;A61P31/12;;A61P37/00;;C12Q1/48;;C12Q1/68;;C12Q1/70,,1,0,,,See references of WO 9211846A1,EXPIRED
91,DE,D1,DE 69325508 D1,128-146-749-105-378,1999-08-05,1999,DE 69325508 T,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,NEUROGRAPHISCHE ABBILDUNGSVERFAHREN UND DIFFUSIONS-ANISTROPIE,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORG S HOSPITAL MEDICAL SC,FILLER AARON;;HOWE FRANKLYN;;TSURUDA JAY;;RICHARDS TODD,,https://lens.org/128-146-749-105-378,Granted Patent,no,0,0,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
92,CA,C,CA 2131705 C,002-043-576-595-223,2008-10-21,2008,CA 2131705 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,IMAGE NEUROGRAPHY AND DIFFUSION ANISOTROPY IMAGING,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e. neurograms) em-ploying a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neu-ral tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/002-043-576-595-223,Granted Patent,no,0,0,11,31,0,G01R33/56341;;G01R33/56341,A61B5/055;;G01R33/34;;G01R33/385;;G01R33/483;;G01R33/56;;G01R33/563;;G01V3/14,,0,0,,,,EXPIRED
93,US,A,US 5560360 A,068-050-656-623-132,1996-10-01,1996,US 2879593 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A,1992-03-09,Image neurography and diffusion anisotropy imaging,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON,FILLER AARON G;;TSURUDA JAY S;;RICHARDS TODD L;;HOWE FRANKLYN A,NEUROGRAFIX (2013-12-27);;UNIVERSITY OF WASHINGTON (1993-06-15);;FILLER AARON G (2013-12-27);;WASHINGTON RESEARCH FOUNDATION (2013-12-27);;WASHINGTON UNIVERSITY OF (2008-02-06);;ST. GEORGE'S HOSPITAL MEDICAL (1993-06-15);;ST. GEORGE'S HOSPITAL MEDICAL SCHOOL (2008-02-01),https://lens.org/068-050-656-623-132,Granted Patent,yes,10,317,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,128/653.2;;324/307,0,0,,,,EXPIRED
94,AU,B2,AU 682146 B2,145-311-910-301-424,1997-09-25,1997,AU 1993/037935 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,Image neurography and diffusion anisotropy imaging,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/145-311-910-301-424,Granted Patent,no,3,0,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
95,WO,A1,WO 1993/018415 A1,132-169-040-569-833,1993-09-16,1993,US 9302036 W,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A,1992-03-09,IMAGE NEUROGRAPHY AND DIFFUSION ANISOTROPY IMAGING,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e. neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/132-169-040-569-833,Patent Application,yes,1,1,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,5,2,109-824-751-456-338;;001-815-837-871-11X,10.1148/radiology.176.2.2367658;;2367658;;1987175;;10.1097/00004728-199101000-00001,"BOOK OF ABSTRACTS, SOCIETY OF MAGNETIC RESONANCE IN MEDICINE, 10TH ANNUAL MEETING 1991, page 913 J. GUY ET AL. 'Fat Suppression Mri: Gd-DTPA Enhancement in Experimental Optic Neuritis';;PATENT ABSTRACTS OF JAPAN vol. 014, no. 265 (C-0726)8 June 1990; & JP,A,2 077 239 ( TOSHIBA CORP ) 16 March 1990;;RADIOLOGY, vol. 176, no. 2, August 1990, EASTON, USA pages 439 - 445 M.E. MOSELEY ET AL. 'Diffusion-weighted MR Imaging of Anisotropic Water Diffusion in Cat Central Nervous System';;JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, vol. 15, no. 1, January 1991, NEW YORK, USA pages 1 - 18 J.V. HAJNAL ET AL. 'MR Imaging of Anisotropically Restricted Diffusion of Water in the Central Nervous System: Technical, Anatomic and Pathologic Considerations';;PATENT ABSTRACTS OF JAPAN vol. 015, no. 341 (C-0863)29 August 1991; & JP,A,3 133 423 ( TOSHIBA CORP ) 6 June 1991",PATENTED
96,AU,A,AU 1993/037935 A,184-815-020-021-889,1993-10-05,1993,AU 1993/037935 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,IMAGE NEUROGRAPHY AND DIFFUSION ANISOTROPY IMAGING,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",ST GEORGES HOSPITAL MEDICAL SCHOOL;;UNIV WASHINGTON,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/184-815-020-021-889,Patent Application,no,0,0,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
97,AT,T1,AT E181773 T1,055-474-157-453-48X,1999-07-15,1999,AT 93907274 T,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A,1992-03-09,NEUROGRAPHISCHE ABBILDUNGSVERFAHREN UND DIFFUSIONS-ANISTROPIE,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/055-474-157-453-48X,Granted Patent,no,0,0,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
98,EP,B1,EP 0630481 B1,139-377-458-535-05X,1999-06-30,1999,EP 93907274 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,IMAGE NEUROGRAPHY AND DIFFUSION ANISOTROPY IMAGING,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/139-377-458-535-05X,Granted Patent,yes,0,0,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,6,5,110-385-436-776-052;;012-699-041-582-658;;042-933-917-860-802;;091-451-337-346-271;;047-441-178-113-918,1652674;;10.1002/mrm.1910190222;;10.1001/jama.1988.03410190120034;;10.1001/jama.260.19.2872;;3141635;;10.1118/1.596675;;2046619;;1667514;;1461131;;10.1002/mrm.1910280215,"P.DOUEK ET AL.: ""Myelin Fiber Orientation Color Mapping"", BOOK OF ABSTRACTS, SOCIETY OF MAGNETIC RESONANCE IN MEDICINE, 10TH ANNUAL MEETING 1991, pages 919;;M.E.MOSELEY ET AL.: ""Anisotropy in Diffusion-Weighted MRI"", MAGNETIC RESONANCE IN MEDICINE, vol. 19, pages 321 - 326;;R.H.GRIFFEY ET AL.: ""Diabetic Neuropathy; Structural Analysis of Nerve Hydration by Magnetic Resonance Spectroscopy"", JAMA, vol. 260, no. 19, pages 2872 - 2878;;S.C.AMARTUR ET AL.: ""Tissue segmentation for three-dimensional display of human spines"", MEDICAL PHYSICS, vol. 18, no. 2, NEW YORK, pages 305 - 308;;M.NAGANUMA ET AL.: ""Chronic inflammatory demyelinating polyradicuroneuropathy associated with multifocal nerve hypertrophy - Report of a case with MRI study."", CLINICAL NEUROLOGY, vol. 31, no. 11, pages 1186 - 1191;;F.A.HOWE ET AL.: ""Magnetic Resonance Neurography"", MAGNETIC RESONANCE IN MEDICINE, vol. 28, pages 328 - 338",EXPIRED
99,CA,A1,CA 2131705 A1,123-896-899-346-661,1993-09-16,1993,CA 2131705 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,IMAGE NEUROGRAPHY AND DIFFUSION ANISOTROPY IMAGING,"2131705 9318415 PCTABS00025 A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e. neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL,FILLER AARON G;;HOWE FRANKLYN A;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/123-896-899-346-661,Patent Application,no,0,0,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
100,EP,A1,EP 0630481 A1,111-393-729-390-416,1994-12-28,1994,EP 93907274 A,1993-03-08,GB 9205058 A;;GB 9205541 A;;GB 9207013 A;;GB 9209648 A;;GB 9210810 A;;GB 9216383 A;;GB 9301268 A;;US 9302036 W,1992-03-09,IMAGE NEUROGRAPHY AND DIFFUSION ANISOTROPY IMAGING.,"A neurography system (10) is disclosed for generating diagnostically useful images of neural tissue (i.e., neurograms) employing a modified magnetic resonance imaging system (14). In one embodiment, the neurography system selectively images neural tissue by employing one or more gradients to discriminate diffusion anisotropy in the tissue and further enhances the image by suppressing the contribution of fat to the image. The neurography system is part of a broader medical system (12), which may include an auxiliary data collection system (22), diagnostic system (24), therapeutic system (26), surgical system (28), and training system (30). These various systems are all constructed to take advantage of the information provided by the neurography system regarding neural networks, which information was heretofore unavailable.",UNIV WASHINGTON;;ST GEORGES HOSP MEDICAL SCHOOL,FILLER AARON G;;HOWE FRANKLYN A CRANMER TERRAC;;TSURUDA JAY S;;RICHARDS TODD L,,https://lens.org/111-393-729-390-416,Patent Application,yes,0,1,11,31,0,G01R33/56341;;G01R33/56341,G01R33/34;;G01R33/385;;G01R33/563,,0,0,,,,EXPIRED
